Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.

Obesity and type 2 diabetes are prevalent in patients with heart failure with preserved ejection fraction and are characterized by a high symptom burden. No approved therapies specifically target obesity-related heart failure with preserved ejection fraction in persons with type 2 diabetes.

Reference: Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.

Go to PubMed